Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al. · The Lancet · 2016
Cited by 2,751 works. doi:10.1016/s0140-6736(16)00587-0
Authors
- Louis Fehrenbacher
- Alexander I. Spira
- Marcus D. Ballinger
- Marcin Kowanetz
- Johan Vansteenkiste
- Julien Mazières
- Keunchil Park
- David Carl Smith
- Angel Artal
- Conrad R. Lewanski
- Fadi Braiteh
- Daniel Waterkamp
- Pei He
- Wei Zou
- Daniel S. Chen
- Jing Yi
- Alan Sandler
- Achim Rittmeyer
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape